Skip Navigation

European Heart Journal 2001 22(12):997-1007; doi:10.1053/euhj.2000.2395
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kalra, P.R
Right arrow Articles by Coats, A.J.S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalra, P.R
Right arrow Articles by Coats, A.J.S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Reviews

The role of C-type natriuretic peptide in cardiovascular medicine

P.R Kalraa,f1, S.D Ankerb, A.D Struthersc and A.J.S Coatsd

a Wessex Cardiac Unit, Southampton, U.K.
b National Heart and Lung Institute, London, U.K.
c Ninewells Hospital and Medical School, Dundee, U.K.
d Royal Brompton and Harefield NHS Trust, London, U.K.

revised July 25, 2000; accepted July 26, 2000

Key Words: C-type natriuretic peptide • atrial natriuretic peptide • brain natriuretic peptide • vasodilatation • vascular regulation • vasopeptidase inhibitors

f1 Correspondence: Dr Paul Kalra, Specialist Registrar in Cardiology, Wessex Cardiac Unit, Level E, East Wing, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, U.K.

References

  1. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg HA. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1991;28:89–94[CrossRef]
  2. Burnett JC Jr, Granger JP, Opgenorth TJ. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol. 1984;247:F863–866[ISI][Medline]
  3. Atarashi K, Mulrow PJ, Franco-Saenz R. Effect of atrial peptides on aldosterone production. J Clin Invest. 1985;76:1807–1811[ISI][Medline]
  4. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988;332:78–81[CrossRef][Medline]
  5. Saito Y, Nakao K, Itoh H. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun. 1989;158:360–368[CrossRef][ISI][Medline]
  6. Hosoda K, Nakao K, Mukoyama M. Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension. 1991;17:1152–1155[Abstract/Free Full Text]
  7. Lang CC, Choy AJ, Struthers AD. Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin Sci. 1992;83:519–527[ISI][Medline]
  8. Burnett JC Jr, Kao PC, Hu DC. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145–1147[Abstract/Free Full Text]
  9. Mukoyama M, Nakao K, Hosoda K. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402–1412[ISI][Medline]
  10. Omland T, Aarsland T, Aakvaag A, Lie RT, Dickstein K. Prognostic value of plasma atrial natriuretic factor, norepinephrine, and epinephrine in acute myocardial infarction. Am J Cardiol. 1993;72:255–259[CrossRef][ISI][Medline]
  11. Darbar D, Davidson NC, Gillespie N. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am J Cardiol. 1996;78:284–287[CrossRef][ISI][Medline]
  12. Richards AM, Doughty R, Nicholls MG. Neurohumoral prediction of benefit from carvedilol in ischaemic left ventricular dysfunction. Circulation. 1999;99:786–792[Abstract/Free Full Text]
  13. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–1130[CrossRef][ISI][Medline]
  14. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of the natriuretic peptide family identified in porcine brain. Biochem Biophys Res Comm. 1990;168:863–870[CrossRef][ISI][Medline]
  15. Komatsu Y, Nakao K, Itoh H, Suga S, Ogawa Y, Imura H. Vascular natriuretic peptide. Lancet. 1992;34:622[CrossRef]
  16. Wei CM, Aarhus LL, Miller VM, Burnett JC Jr. The action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol. 1993;264:H71–73[ISI][Medline]
  17. Nakamura M, Arakawa N, Funakoshi T, Yoshida H, Hiramori K. Vasodilatory effect of C-type natriuretic peptide on forearm resistance vessels is distinct from atrial natriuretic peptide in patients with congestive heart failure (Abstr). Circulation. 1993;88:I-256
  18. Tawaragi Y, Fuchimura K, Tanaka S, Minamino N, Kangawa K, Matsuo H. Gene and precursor structures of human C-type natriuretic peptide. Biochem Biophys Res Commun. 1991;175:645–651[CrossRef][ISI][Medline]
  19. Stingo AJ, Clavell AL, Heublein DM, Wei CM, Pittelkow MR, Burnett JC Jr. Presence of C-type natriuretic peptide in cultured human endothelial cells and human plasma. Am J Physiol. 1992;263:H1318–1321[ISI][Medline]
  20. Togashi K, Kameya T, Kurosawa T, Hasegawa N, Kawakami M. Concentrations and molecular forms of C-type natriuretic peptide in brain and cerebrospinal fluid. Clin Chem. 1992;38:2136–2139[Abstract]
  21. Chinkers M, Garbers DL. The protein kinase domain of the ANP receptor is required for signalling. Science. 1989;245:1392–1394[Abstract/Free Full Text]
  22. Suga S, Nakao K, Hosoda K. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 1992;130:229–239[Abstract]
  23. Almeida FM, Suzuki M, Scarborough RM, Lewicki JA, Maack T. Clearance function of type C receptors of atrial natriuretic factor in rats. Am J Physiol. 1989;256:R469–475[ISI][Medline]
  24. Levin ER. Natriuretic peptide C-receptor: more than a clearance receptor. Am J Physiol. 1993;264:E483–489[ISI][Medline]
  25. Takida S, Elmquist BJ, Trachte GJ. C-type natriuretic peptide attenuates evoked dopamine efflux by influencing Go{alpha}. Hypertension. 1999;33:124–129[Abstract/Free Full Text]
  26. Kourie JI. Synthetic mammalian C-type natriuretic peptide forms large cation channels. FEBS Lett. 1999;445:57–62[CrossRef][ISI][Medline]
  27. Cermak R, Kleta R, Forssmann WG, Schlatter E. Natriuretic peptides increase K+ conductance in rat mesangial cells. Pflugers Archiv—Euro J Physiol. 1996;431:571–577[CrossRef]
  28. Wei CM, Hu S, Miller VM, Burnett JC Jr. Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem Biophys Res Commun. 1994;205:765–771[CrossRef][ISI][Medline]
  29. Soleilhac JM, Lucas E, Beaumont A. A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium. Mol Pharmacol. 1992;41:609–614[Abstract]
  30. Kenny AJ, Stephenson SL, Turner AJ. Cell surface peptidases. Kenny AJ, Turner AJ. Mammalian Ectoenzymes. Amsterdam: Elsevier; 1987. p. 169–210
  31. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase 24.11. Biochem J. 1993;291:83–88[ISI][Medline]
  32. Totsune K, Takahashi K, Ohneda M, Itoi K, Murakami O, Mouri T. C-type natriuretic peptide in the human central nervous system: distribution and molecular form. Peptides. 1994;15:7–40[CrossRef][ISI][Medline]
  33. Mattingly MT, Brandt RR, Heublein DM, Wei C, Nir A, Burnett JC Jr. Presence of C-type natriuretic peptide in human kidney and urine. Kidney Int. 1994;46:744–747[ISI][Medline]
  34. Takahashi T, Allen PD, Izumo S. Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing ventricles. Circ Res. 1992;71:9–17[Abstract/Free Full Text]
  35. Nunez DJR, Dickson CM, Brown KJ. Natriuretic peptide receptor mRNAs in the rat and human heart. J Clin Invest. 1992;90:1966–1971[ISI][Medline]
  36. Wei CM, Heublein DM, Perrella MA. Natriuretic peptide system in human heart failure. Circulation. 1993;88:1004–1009[Abstract/Free Full Text]
  37. Suga S, Nakao K, Itoh H. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-ß. J Clin Invest. 1992;90:1145–1149[ISI][Medline]
  38. Suga S, Itoh H, Komatsu Y. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells—evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology. 1993;133:3038–3041[Abstract]
  39. Marumo T, Nakaki T, Hishikawa K. Natriuretic peptide-augmented induction of nitric oxide synthase through cyclic guanosine 3',5'-monophosphate elevation in vascular smooth muscle cells. Endocrinology. 1995;136:2135–2142[Abstract]
  40. Nazario B, Hu RM, Pedram A, Prins B, Levin ER. Atrial and brain natriuretic peptides stimulate the production and secretion of C-type natriuretic peptide from bovine aortic endothelial cells. J Clin Invest. 1995;95:1151–1157[ISI][Medline]
  41. Kohno M, Horio T, Yokokawa K, Kurihara N, Takeda T. C-type natriuretic peptide inhibits thrombin and angiotensin II stimulated endothelin release via cyclic guanosine 3',5'-monophosphate. Hypertension. 1992;19:320–325[Abstract/Free Full Text]
  42. Dietz JR. Release of natriuretic factor from rat heart-lung preparation by atrial distension. Am J Physiol. 1984;247:R1093–1096[Medline]
  43. Lang CC, Coutie WJ, Khong TK, Choy AMJ, Struthers AD. Dietary sodium loading increases plasma brain natriuretic peptide levels in man. J Hypertens. 1991;9:779–782[CrossRef][ISI][Medline]
  44. Lang CC, Choy AMJ, Henderson IS, Coutie WJ, Struthers AD. Effect of haemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure. Clin Sci. 1992;82:127–131[ISI][Medline]
  45. Tsutamoto T, Wada A, Maeda K. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Circulation. 1997;96:509–516[Abstract/Free Full Text]
  46. Hunt PJ, Richards AM, Espiner EA, Nicholls MG, Yandle TG. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab. 1994;78:1428–1435[Abstract]
  47. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and haemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993;76:91–96[Abstract]
  48. Totsune K, Takahashi K, Murakami O, Satoh F, Sone M, Mouri T. Elevated plasma C-type natriuretic peptide concentrations in patients with chronic renal failure. Clin Sci. 1994;87:319–322[ISI][Medline]
  49. Cargill RI, Barr CS, Coutie WJ, Struthers AD, Lipworth BJ. C-type natriuretic peptide levels in cor pulmonale and in congestive cardiac failure. Thorax. 1994;49:1247–1249[Abstract]
  50. Baertschi AJ, Adams JM, Sullivan MP. Acute hypoxaemia stimulates atrial natriuretic factor secretion in vivo. Am J Physiol. 1988;255:H295–300[Medline]
  51. Hama N, Itoh H, Shirakami G. Detection of C-type natriuretic peptide in human circulation and marked increase of plasma CNP level in septic shock patients. Biochem Biophys Res Commun. 1994;198:1177–1182[CrossRef][ISI][Medline]
  52. Wang P, Zhou M, Ba ZF, Cioffi WG, Chaudry IH. Up-regulation of a novel potent vasodilatory peptide adrenomedullin during polymicrobial sepsis. Shock. 1998;10:118–122[ISI][Medline]
  53. Kilbourn RG, Jubran A, Gross SG. Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun. 1990;172:1132–1138[CrossRef][ISI][Medline]
  54. Cheung BM, Brown MJ. Plasma brain natriuretic peptide and C-type natriuretic peptide in essential hypertension. J Hyperts. 1994;12:449–454[ISI][Medline]
  55. Stepan H, Faber R, Walther D, Walther T. C-type natriuretic peptide levels in women with gestational hypertension and pre-eclampsia. Obstet Gynecol. 1999;93:199–202[Abstract/Free Full Text]
  56. Mutafova-Yambolieva VN, Westfall DP. Modulatory effects of C-type natriuretic peptide on sympathetic cotransmission in the rat isolated tail artery. Clinical and Experimental Pharmacology and Physiology. 1998;25:1013–1017[ISI][Medline]
  57. Dunselman PHJM, Kuntze EE, van Bruggen A. Value of New York Heart Association classification, radionucleotide ventriculography, and cardiopulmonary exercise tests for selection of patients for congestive heart failure studies. Am Heart J. 1988;116:1475–1482[CrossRef][ISI][Medline]
  58. Zimmerman RS, Edwards BS, Schwab TR, Heublein DM, Burnett JC Jr. Cardiorenal-endocrine dynamics during and following volume expansion. Am J Physiol. 1987;252:R336–340[ISI][Medline]
  59. Borgeson DD, Stevens TL, Heublein DM, Matsuda Y, Burnett JC. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism. Clin Sci. 1998;95:195–202[CrossRef][ISI][Medline]
  60. Agnoletti G, Cornacchiari A, Panzali AF, Ghielmi S, De Giuli F, Ferrari R. Effect of congestive heart failure on rate of atrial natriuretic factor release in response to stretch and isoprenaline. Cardiovasc Res. 1990;24:938–945[ISI][Medline]
  61. Matsubara H, Umeda Y, Nishikawa M. Heart with circulatory failure secretes and processes atrial natriuretic peptide in a manner different to normal heart. Clin Cardiol. 1988;11:197–203[ISI][Medline]
  62. Totsune K, Takahashi K, Murakami O. Natriuretic peptides in the human kidney. Hypertension. 1994;24:758–762[Abstract/Free Full Text]
  63. Canaan-Kuhl S, Jamison RL, Myers BD, Pratt RE. Identification of ‘B’ receptor for natriuretic peptide in human kidney. Endocrinology. 1992;130:550–552[Abstract]
  64. Wei CM, Aarhus LL, Miller VM, Schaff HV, Burnett JC Jr. The actions of natriuretic peptides on isolated human saphenous veins and internal mammary arteries (Abstr). J Am Coll Cardiol. 1994;23:177A
  65. Schwartz SM. Smooth muscle migration in vascular development and pathogenesis. Transpl Immunol. 1997;5:255–260[CrossRef][ISI][Medline]
  66. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest. 1990;86:1690–1697[ISI][Medline]
  67. Itoh H, Pratt RE, Ohno M, Dzau VJ. Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells. Hypertension. 1992;19:758–761[Abstract/Free Full Text]
  68. Furuya M, Yoshida M, Hayashi Y. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1991;177:927–931[CrossRef][ISI][Medline]
  69. Porter JG, Catalano R, McEnroe G, Lewicki JA, Protter AA. C-type natriuretic peptide inhibits growth factor-dependent DNA synthesis in smooth muscle cells. Am J Physiol. 1992;263:C1001–1006[ISI][Medline]
  70. Majesky MW, Linder V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor ß1during repair of arterial injury. J Clin Invest. 1991;88:904–910[ISI][Medline]
  71. Ikeda M, Kohno M, Yasunari K. Natriuretic peptide family as a novel antimigration factor of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997;17:731–736[Abstract/Free Full Text]
  72. Brown C, Pan X, Hassid A. Nitric oxide and C-type atrial natriuretic peptide stimulate primary aortic smooth muscle cell migration via a cGMP-dependent mechanism. Circ Res. 1999;84:655–667[Abstract/Free Full Text]
  73. Hamdan AD, Quist WC, Gagne JB, Feener EP. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation. 1996;93:1073–1078[Abstract/Free Full Text]
  74. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin {alpha}vß3binding to vitronectin. Nature. 1996;383:441–443[CrossRef][Medline]
  75. Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1998;18:1771–1779[Abstract/Free Full Text]
  76. Yoshizumi M, Tsuji H, Nishimura H. Natriuretic peptides regulate the expression of tissue factor and PAI-1 endothelial cells. Thromb Haemost. 1999;82:1497–1503[ISI][Medline]
  77. Suenobu N, Shichiri M, Iwashina M, Marumo F, Hirata Y. Natriuretic peptides and nitric oxide induce endothelial apoptosis via a cGMP-dependent mechanism. Arterioscler Thromb Vasc Biol. 1999;19:140–146[Abstract/Free Full Text]
  78. Stingo AJ, Clavell AL, Aarhus LL, Burnett JC Jr. Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol. 1992;262:H308–312[ISI][Medline]
  79. Chien YW, Frohlich ED, Trippodo NC. Atrial natriuretic peptide increases resistance to venous return in rats. Am J Physiol. 1987;252:H894–899[ISI][Medline]
  80. Beaulieu P, Cardinal R, Page P, Francoeur F, Tremblay J, Lambert C. Positive chrontropic and inotropic effects of C-type natriuretic peptide in dogs. Am J Physiol. 1997;273:H1933–1940[ISI][Medline]
  81. Irisawa H, Brown HF, Giles W. Cardiac pacemaking in the sinoatrial node. Physiol Rev. 1993;73:197–227[Free Full Text]
  82. Hirose M, Furukawa Y, Miyashita Y. CNP causes receptor-mediated positive dromotrophic effects in anaesthetized dog hearts. Am J Physiol. 1998;275:H717–720[Medline]
  83. Brusq J-M, Mayoux E, Guigui L, Kirilovsky J. Effects of C-type natriuretic peptide on rat cardiac contractility. Br J Pharmacol. 1999;128:206–212[CrossRef][ISI][Medline]
  84. Neyses L, Vetter H. Action of atrial natriuretic peptide and angiotensin II on the myocardium: studies in isolated rat ventricular cardiomyocytes. Biochem Biophys Res Commun. 1989;163:1435–1443[CrossRef][ISI][Medline]
  85. Tajima M, Bartunek J, Weinberg EO, Itoh N, Lorell BH. Atrial natriuretic peptide has different effects on contractility and intracellular pH in normal and hypertrophied myocytes from pressure overloaded hearts. Circulation. 1998;98:2760–2764[Abstract/Free Full Text]
  86. Schultz HD, Gardner DG, Deschepper CF, Coleridge HM, Coleridge JC. Vagal C-fiber blockade abolishes sympathetic inhibition by atrial natriuretic factor. Am J Physiol. 1988;155:R6–13
  87. Yang RH, Jin HK, Wyss JM, Chen YF, Oparil S. Pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii. Hypertension. 1992;19:198–205[Abstract/Free Full Text]
  88. Thomas CJ, Head GA, Woods RL. Similar baroreflex bradycardic actions of atrial natriuretic peptide and B and C types of natriuretic peptides in conscious rats. J Hypertens. 1999;17:801–806[CrossRef][ISI][Medline]
  89. Ebert TJ, Cowley AW. Atrial natriuretic factor attenuates carotid baroreflex-mediated cardioacceleration in humans. Am J Physiol. 1988;254:R590–594[ISI][Medline]
  90. Volpe M, Lembo G, De Luca N. Converting enzyme inhibition prevents the effects of atrial natriuretic factor on arterial baroreflexes. Circulation. 1990;82:1214–1221[Abstract/Free Full Text]
  91. Furuya M, Aisaka K, Miyazaki T. C-type natriuretic peptide inhibits intimal thickening after vascular injury. Biochem Biophys Res Commun. 1993;193:248–253[CrossRef][ISI][Medline]
  92. Shinomiya M, Tashiro J, Saito Y. C-type natriuretic peptide inhibits intimal thickening of rabbit carotid artery after balloon catheter injury. Biochem Biophys Res Commun. 1994;205:1051–1056[CrossRef][ISI][Medline]
  93. Ueno H, Haruno A, Morisaki N. Local expression of C-type natriuretic peptide markedly suppresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation. 1997;96:2272–2279[Abstract/Free Full Text]
  94. Richards A, Tonolo G, Montorsi P. Low dose infusions of 26- and 28-amino acid human atrial natriuretic peptides in normal man. J Clin Endocrinol Metab. 1988;66:465–472[Abstract]
  95. Cozen EN, Foecking MF, Vila MC, Gomez-Sanchez CE. Adrenal receptors for natriuretic peptides and inhibition of aldosterone secretion in calf zona glomerulosa cells in culture. Acta Endocrinol. 1993;129:59–64
  96. Cargill RI, Struthers AD, Lipworth BJ. Human C-type natriuretic peptide: effects on the haemodynamic and endocrine responses to angiotensin II. Cardiovasc Res. 1995;29:108–111[CrossRef][ISI][Medline]
  97. Cargill RI, Struthers AD, Lipworth BJ. Comparative effects of atrial natriuretic peptide and brain natriuretic peptide on the aldosterone and pressor responses to angiotensin II in man. Clin Sci. 1995;88:81–86[Medline]
  98. Barletta G, Lazzeri C, Vecchiarino S. Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans. Hypertension. 1998;31:802–808[Abstract/Free Full Text]
  99. Barr CS, Davidson NC, Lang CC, Struthers AD. Cardiovascular and neuroendocrine effects of CNP in healthy man (Abstr). J Hum Hypertens. 1994;8:655–656
  100. Igaki T, Itoh H, Suga S. C-type natriuretic peptide in chronic renal failure and its action in humans. Kidney Int. 1996;49:S144–147
  101. Pham I, Sediame S, Maistre G. Renal and vascular effects of C-type and atrial natriuretic peptides in humans. Am J Physiol. 1997;273:R1457–1464[ISI][Medline]
  102. Nakamura M, Arakawa N, Yoshida H, Makita S, Hiramori K. Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure. Circulation. 1994;90:1210–1214[Abstract/Free Full Text]
  103. Tsutamoto T, Kanamori T, Morigami N, Sugimoto Y, Yamaoka O, Kinoshita M. Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with severe chronic heart failure. Circulation. 1993;87:70–75[Abstract/Free Full Text]
  104. Schiffrin EL. Decreased density of binding sites for atrial natriuretic peptide on platelets of patients with severe congestive heart failure. Clin Sci. 1988;74:213–218[ISI][Medline]
  105. Hirooka Y, Takeshita A, Imaizumi T. Attenuated forearm vasodilative response to intra-arterial atrial natriuretic peptide in patients with heart failure. Circulation. 1990;82:147–153[Abstract/Free Full Text]
  106. Crozier IG, Nicholls MG, Ikram H, Espiner EA, Gomez HJ, Warner NJ. Haemodynamic effects of atrial peptide infusion in heart failure. Lancet. 1986;2:1242–1245[ISI][Medline]
  107. Kurtz A, Della Bruna R, Pfeilschifter J, Taugner R, Bauer C. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc Natl Acad Sci USA. 1986;83:4769–4773[Abstract/Free Full Text]
  108. Oelkers W, Kleiner S, Bahr V. Effects of incremental infusions of atrial natriuretic factor on aldosterone, renin and blood pressure in humans. Hypertension. 1988;12:462–467[Abstract/Free Full Text]
  109. Kawaguchi H, Sawa H, Yasuda H. Effect of atrial natriuretic factor on angiotensin converting enzyme. J Hypertens. 1990;8:749–753[CrossRef][ISI][Medline]
  110. Davidson NC, Barr CS, Struthers AD. C-type natriuretic peptide: an endogenous inhibitor of vascular angiotensin-converting enzyme activity. Circulation. 1996;93:1155–1159[Abstract/Free Full Text]
  111. Margulies KB, Perrella MA, McKinlay LJ, Burnett JC Jr. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest. 1991;88:1636–1642[ISI][Medline]
  112. Trippodo NC, Robl JA, Asaad MM. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens. 1998;11:363–372[CrossRef][ISI][Medline]
  113. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad M. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharm. 1999;34:782–790[CrossRef][ISI][Medline]
  114. Melo LG, Veress AT, Ackermann U, Pang SC, Flynn TG, Sonnenberg H. Chronic hypertension in ANP knockout mice: contribution of peripheral resistance. Regulatory Peptides. 1999;79:109–115[CrossRef][ISI][Medline]
  115. Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension. 1999;33:219–224[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
C. Sengenes, A. Bouloumie, H. Hauner, M. Berlan, R. Busse, M. Lafontan, and J. Galitzky
Involvement of a cGMP-dependent Pathway in the Natriuretic Peptide-mediated Hormone-sensitive Lipase Phosphorylation in Human Adipocytes
J. Biol. Chem., December 5, 2003; 278(49): 48617 - 48626.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. R. Kalra, J. R. Clague, A. P. Bolger, S. D. Anker, P. A. Poole-Wilson, A. D. Struthers, and A. J. Coats
Myocardial Production of C-Type Natriuretic Peptide in Chronic Heart Failure
Circulation, February 4, 2003; 107(4): 571 - 573.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P.R. Kalra, P.P. Ponikowski, and S.D. Anker
Sympathetic activation and malignant ventricular arrhythmias: a molecular link?
Eur. Heart J., July 2, 2002; 23(14): 1078 - 1080.
[Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kalra, P.R
Right arrow Articles by Coats, A.J.S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalra, P.R
Right arrow Articles by Coats, A.J.S
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?